Tardimed

ABOUT US

TardiMed Sciences is a Life Sciences Investment and Company Creation Firm

We are investors. We are operators. We are entrepreneurs.

We identify unique opportunities in the life sciences, create companies around these opportunities, and then provide the financing and management to seed their growth.

Strategies

Think Big

We identify opportunities that have the potential to make a major impact for the people they target.

Be Creative

There is always more than one way to achieve one’s goals and it is often the path least traveled that may yield the greatest results. We always evaluate this path and frequently take it.

Manage Risk

We seek opportunities with proven clinical data, established markets, and the potential to achieve key milestones in a rapid and cost-effective manner.

Act Efficiently

We invest wisely, operate leanly and have a laser focus on the achievement of key near term milestones.

Leadership

Partner

Zachary Rome

Zach is a biopharmaceutical inventor, entrepreneur and executive. He is a Partner at TardiMed where he has Co-Founded several life science companies that span multiple therapeutic areas and stages of development. He also serves in an operating role for several of the TardiMed portfolio companies and is currently the President and a member of the Board of Directors for Timber Pharmaceuticals.

Previously, Zach was the Co-Founder and President at Patagonia Pharmaceuticals, a privately-owned specialty pharmaceutical company developing treatments for rare dermatologic diseases. He was the lead inventor on all of Patagonia’s technologies and oversaw their development from concept through Phase 2 studies. In 2018, Patagonia was awarded a $1.5 million grant from the FDA for which Zach served as the Principal Investigator. Zach has a BS in Marine Science and Biology from the University of Miami and an MST in Adolescent Science Biology from Pace University.

Managing Partner

Michael Derby

Michael is a successful biopharmaceutical entrepreneur, operating executive and investor. He has founded or co-founded multiple biopharmaceutical companies and has a passion for developing and commercializing innovative products that make a major impact on the lives of patients globally.

Michael is the Founder and Managing Partner of TardiMed Sciences, which is building a portfolio of innovative companies that address some of medicine’s most pressing diseases. In 2015, Michael co-founded Castle Creek Pharmaceuticals which, under his leadership, raised more than $120 million and was built into a late clinical-stage company developing important therapies for patients with rare dermatologic conditions. Prior to Castle Creek, Michael founded Norphan Pharmaceuticals, which developed drugs for patients with rare neurologic diseases, including one of the first drugs to gain U.S. FDA approval for the treatment of Duchenne muscular dystrophy. Earlier in his career, Michael was a venture capitalist and operating executive, holding key commercial roles at Merck & Co. and Forest Laboratories.

Michael holds advanced degrees in business and science, with an MBA, with distinction, from New York University’s Stern School of Business, an MS in Neuroscience from the University of Rochester, and a BS, with honors, from Johns Hopkins University.